• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research

Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment
Abstract Target specific anticoagulants (TSOACs) have recently been introduced to the US market for multiple indications including venous thromboembolism (VTE) prevention in total hip and knee replacement surgeries, VTE treatment and reduction in the risk of stroke in patients with non-valvular atrial fibrillation (NVAF). Currently, three TSOACs are available including rivaroxaban, apixaban, and dabigatran with edoxaban currently under Food and Drug Administration review for VTE treatment and stroke prevention in NVAF. The introduction of these agents has created a paradigm shift in anticoagulation by considerably...
Source: Journal of Thrombosis and Thrombolysis - January 21, 2015 Category: Hematology Source Type: research

Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
In conclusion, preventing patients with cardiovascular disease from discontinuing ASA could result in substantial clinical and economic gains. PMID: 24008261 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 5, 2013 Category: Hematology Authors: Cea Soriano L, Garcia Rodriguez L, Bueno H, Lanas A Tags: Thromb Haemost Source Type: research

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment.
Source: Thrombosis Research - December 12, 2014 Category: Hematology Authors: A.T. Cohen, S. Imfeld, J. Markham, S. Granziera Tags: Review Article Source Type: research

Incidence and prevalence of venous thromboembolism in Norway 2010 –2017
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a major cause of mortality and morbidity, and is associated with reduced survival, substantial healthcare costs, and high recurrence rates [1]. It is the third-leading cardiovascular disorder, after myocardial infarction and stroke with approximately 10 million global cases diagnosed annually [2].
Source: Thrombosis Research - July 6, 2020 Category: Hematology Authors: Waleed Ghanima, Ellen Brodin, Anna Schultze, Leah Shepherd, Dimitra Lambrelli, Maria Ulvestad, Sreeram Ramagopalan, Sigrun Halvorsen Tags: Letter to the Editors-in-Chief Source Type: research